Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging, announced today that the National Institute of
Aging (NIA) has selected one of its SIRT1 activators for an
Interventions Testing Program to study the effects of SIRT1 activation
on aging.
"We are delighted to be working with the National Institute of Aging on
this important aging study, testing the effects of SIRT1 activation for
diseases of aging. This is another step forward in advancing our
platform of SIRT1 activators," said Christoph Westphal, M.D., Ph.D.,
Chief Executive Officer and Vice Chair of Sirtris Pharmaceuticals.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators for diseases of aging, the progress and
results of pre-clinical studies of SIRT1 activators, and the potential
of sirtuin modulators to receive regulatory approval. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack of
results that would provide a basis for predicting whether any of the
Company’s product candidates will be safe or
effective, or receive regulatory approval, the possibility that results
of pre-clinical studies are not necessarily predictive of clinical trial
results, the Company's potential inability to initiate and complete
pre-clinical studies and clinical trials for its product candidates, the
fact that none of the Company's product candidates has received
regulatory approvals, the potential inability of the Company to gain
market acceptance of the Company's product candidates, and those other
risks factors that can be found in the Company's filings with the
Securities and Exchange Commission. Actual results may differ materially
from those Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.